A detailed history of Fine Mark National Bank & Trust transactions in Biogen Inc. stock. As of the latest transaction made, Fine Mark National Bank & Trust holds 1,535 shares of BIIB stock, worth $285,018. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,535
Previous 1,652 7.08%
Holding current value
$285,018
Previous $356,000 0.28%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 02, 2024

SELL
$190.52 - $236.72 $22,290 - $27,696
-117 Reduced 7.08%
1,535 $355,000
Q1 2024

May 14, 2024

BUY
$212.02 - $267.71 $114,490 - $144,563
540 Added 48.56%
1,652 $356,000
Q4 2023

Feb 09, 2024

SELL
$222.59 - $267.94 $30,272 - $36,439
-136 Reduced 10.9%
1,112 $287,000
Q3 2023

Nov 15, 2023

BUY
$253.3 - $285.89 $6,332 - $7,147
25 Added 2.04%
1,248 $320,000
Q2 2023

Aug 11, 2023

BUY
$275.25 - $318.06 $7,707 - $8,905
28 Added 2.34%
1,223 $348,000
Q1 2023

May 08, 2023

SELL
$256.56 - $292.34 $252,968 - $288,247
-986 Reduced 45.21%
1,195 $332,000
Q4 2022

Feb 09, 2023

SELL
$252.44 - $306.72 $11,864 - $14,415
-47 Reduced 2.11%
2,181 $603,000
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $1,557 - $2,147
8 Added 0.36%
2,228 $595,000
Q2 2022

Aug 09, 2022

BUY
$187.54 - $223.02 $6,001 - $7,136
32 Added 1.46%
2,220 $453,000
Q1 2022

May 16, 2022

SELL
$193.77 - $244.14 $88,552 - $111,571
-457 Reduced 17.28%
2,188 $461,000
Q4 2021

Feb 14, 2022

SELL
$223.92 - $287.77 $12,763 - $16,402
-57 Reduced 2.11%
2,645 $635,000
Q3 2021

Nov 12, 2021

SELL
$282.99 - $369.05 $11,602 - $15,131
-41 Reduced 1.49%
2,702 $765,000
Q2 2021

Aug 13, 2021

SELL
$259.0 - $414.71 $41,181 - $65,938
-159 Reduced 5.48%
2,743 $950,000
Q1 2021

May 12, 2021

SELL
$242.95 - $284.63 $7,288 - $8,538
-30 Reduced 1.02%
2,902 $812,000
Q4 2020

Feb 10, 2021

BUY
$236.26 - $355.63 $7,560 - $11,380
32 Added 1.1%
2,932 $718,000
Q3 2020

Nov 12, 2020

SELL
$264.77 - $305.71 $24,888 - $28,736
-94 Reduced 3.14%
2,900 $823,000
Q2 2020

Aug 13, 2020

BUY
$258.66 - $342.55 $10,087 - $13,359
39 Added 1.32%
2,994 $801,000
Q1 2020

May 06, 2020

BUY
$268.85 - $341.04 $29,573 - $37,514
110 Added 3.87%
2,955 $935,000
Q4 2019

Feb 07, 2020

BUY
$220.06 - $304.07 $10,782 - $14,899
49 Added 1.75%
2,845 $844,000
Q3 2019

Nov 08, 2019

SELL
$217.44 - $243.88 $2,391 - $2,682
-11 Reduced 0.39%
2,796 $650,000
Q2 2019

Aug 08, 2019

BUY
$219.29 - $241.72 $151,748 - $167,270
692 Added 32.72%
2,807 $656,000
Q1 2019

May 07, 2019

SELL
$216.71 - $338.96 $66,529 - $104,060
-307 Reduced 12.68%
2,115 $500,000
Q4 2018

Feb 07, 2019

BUY
$278.5 - $352.75 $250,093 - $316,769
898 Added 58.92%
2,422 $729,000
Q3 2018

Nov 02, 2018

SELL
$293.51 - $383.83 $2.02 Million - $2.64 Million
-6,880 Reduced 81.87%
1,524 $538,000
Q2 2018

Aug 03, 2018

BUY
$257.52 - $306.91 $173,053 - $206,243
672 Added 8.69%
8,404 $2.44 Million
Q1 2018

Apr 26, 2018

BUY
$260.13 - $367.91 $666,713 - $942,953
2,563 Added 49.58%
7,732 $2.12 Million
Q4 2017

Jan 30, 2018

BUY
$307.64 - $344.58 $383,011 - $429,002
1,245 Added 31.73%
5,169 $1.65 Million
Q3 2017

Oct 30, 2017

BUY
$281.15 - $329.69 $1.1 Million - $1.29 Million
3,924
3,924 $1.23 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $26.7B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Fine Mark National Bank & Trust Portfolio

Follow Fine Mark National Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fine Mark National Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Fine Mark National Bank & Trust with notifications on news.